ANTARES PHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1979-01-01
- Employees
- 201
- Market Cap
- -
- Website
- http://www.antarespharma.com
Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism
Phase 2
Completed
- Conditions
- Hypogonadism
- Interventions
- Combination Product: Testosterone enanthate auto-injector
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02777242
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
Phase 3
Completed
- Conditions
- Hypogonadism
- Interventions
- Combination Product: Testosterone enanthate auto-injector
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02504541
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
Phase 1
Completed
- Conditions
- Hypogonadism
- Interventions
- Combination Product: Testosterone enanthate auto-injector
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02233751
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
Phase 3
Completed
- Conditions
- Hypogonadism
- Interventions
- Combination Product: Testosterone enanthate auto-injector
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02159469
Pharmacokinetic Study of Testosterone Enanthate
Phase 1
Completed
- Conditions
- Hypogonadism
- Interventions
- Drug: QuickShot™ - 100 mg Treatment ADrug: QuickShot™ - 50 mg Treatment B
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01887418
- Locations
- 🇺🇸
Mens Health Boston, Brookline, Massachusetts, United States
Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01737944
- Locations
- 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01618968
- Locations
- 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Device: VIBEX MTX
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01618955
- Locations
- 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Phase 3
Completed
- Conditions
- Urge Urinary IncontinenceUrinary Frequency
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 626
- Registration Number
- NCT00909181
© Copyright 2025. All Rights Reserved by MedPath